Results 171 to 180 of about 200,281 (336)

Microvascular obstruction in cardiac amyloidosis

open access: yes
European Journal of Heart Failure, EarlyView.
Lucrezia Netti   +19 more
wiley   +1 more source

Urinary markers in heart failure – types, timing and thresholds. European Journal of Heart Failure expert consensus document

open access: yesEuropean Journal of Heart Failure, EarlyView.
Pathophysiologic mechanisms of heart failure (HF) (i.e. renin–angiotensin–aldosterone system [RAAS], congestion, and inflammation), together with patient‐related factors such as diabetes, hypertension, and chronic kidney disease (CKD), contribute to kidney function decline and glomerular or tubular injury.
Masatake Kobayashi   +14 more
wiley   +1 more source

Renal Response Criteria for Clinical Trials in Amyloid Light Chain Amyloidosis

open access: yesKidney International Reports
Immunoglobin light chain (AL) amyloidosis is a rare disease characterized by organ deposition of amyloid fibrils, most commonly in the heart and kidney.
Nelson Leung   +11 more
doaj   +1 more source

AA amyloidosis in a patient with Langerhans cell histiocytosis [PDF]

open access: hybrid, 2011
Peter C. Thomson   +4 more
openalex   +1 more source

Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis

open access: yesCirculation, 2016
J. Gillmore   +31 more
semanticscholar   +1 more source

A functional role for spontaneously occurring natural anti‐transthyretin antibodies from patients with transthyretin cardiac amyloidosis

open access: yes
European Journal of Heart Failure, EarlyView.
Ortal Tuvali   +5 more
wiley   +1 more source

Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS‐B trial

open access: yesEuropean Journal of Heart Failure, EarlyView.
Summary of the HELIOS‐B trial design. Right: Forest (top) and spline (bottom) plots demonstrating the effect of vutrisiran versus placebo on clinical outcomes across age groups in HELIOS‐B. Age‐stratified outcomes with vutrisiran in transthyretin amyloid cardiomyopathy.
Awais Sheikh   +8 more
wiley   +1 more source

The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma

open access: yesHemaSphere
The 2/20/20 International Myeloma Working Group (IMWG) score is the most employed risk score in clinical practice to evaluate the risk of progression from smoldering multiple myeloma (SMM) to symptomatic multiple myeloma.
Anna deDaniel   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy